| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_905308afe30a5316da6d821114a471a9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042 |
| filingDate |
1992-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8b9d234e159a8030e4ee9773fd63812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ec390db312ae33cc88205347c717e12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a20d618ea533e58eab773b0eeedaffd |
| publicationDate |
1993-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0560967-A1 |
| titleOfInvention |
Use of aica riboside compounds for the treatment and prevention of tissue damage due to decreased blood flow |
| abstract |
A method of preventing tissue damage associated with reduced blood flow in a human, and comprising administering an AICA riboside or a prodrug of that riboside in an amount ensuring a concentration of blood plasma between 1 mug / ml and 20 mug / ml AICA riboside for a time sufficient to reduce the risk of tissue damage in this human being. Methods of preventing clinical accidents, such as a cardiovascular and / or cerebrovascular problem in a patient at risk include administering an AICA riboside or a prodrug thereof in an amount ensuring a concentration of blood plasma between 1 mug / ml and 20 mug / ml AICA riboside for a time sufficient to reduce the risk in this patient. |
| priorityDate |
1991-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |